About Inex Medicaments Private Limited
Data last updated:
Inex Medicaments Private Limited is a private limited company based in Chennai, Tamil Nadu, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 06 November 2009 and has been in existence for over 17 years.
The company is registered with the Registrar of Companies (ROC), Chennai, under CIN U51909TN2009PTC073452. Its GSTIN is 33AACCI1653E1Z2 (Tamil Nadu).
The company has an authorised share capital of ₹5 Lakh and a paid-up capital of ₹5 Lakh. It is led by directors Gopalakrishnan Srinivasan (Managing Director) and Banumathi Srinivasan.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at No.22 Villa A&B Second Floor Rajiv Street Kamaraj Nagar Keelkatta, Chennai, Tamil Nadu, India – 600117.
As per the financials filed for FY 2025, the company reported a revenue of ₹6.31 Cr, a growth of 13% compared to the previous year. For the same year it recorded a net profit of ₹20.44 Lakh (net margin 3.2%) and EBITDA of ₹45.45 Lakh (EBITDA margin 7.2%). Revenue has grown at a compounded annual rate (CAGR) of 8% over three years and 3% over five years.
As per MCA filings, the company has open charges of ₹2.25 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website inexmedicaments.com.
Company details
Contact details
Inex Medicaments Private Limited's registered office is in Chennai, Tamil Nadu. Its website is inexmedicaments.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressNo.22 Villa A&B Second Floor Rajiv Street Kamaraj Nagar Keelkatta, Chennai, Tamil Nadu, India – 600117
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Inex Medicaments Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Inex Medicaments is trade. In detail, this covers wholesale trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Inex Medicaments Private Limited, buy the company report.
Financials of Inex Medicaments Private Limited
FY 2025 filings availableInex Medicaments Private Limited reported revenue of ₹6.31 Cr (up 13% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 3% over five years, including 13% growth in the latest year. EBITDA fell 10% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹45.45 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹20.44 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 7.2% | ||||
| Net Profit Margin | 3.2% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Inex Medicaments Private Limited, buy the company report.
Board of directors of Inex Medicaments Private Limited
Inex Medicaments has 2 current directors and 10 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Gopalakrishnan Srinivasan | Managing Director | 06 Nov 2009 | 17 Years 0 Months | Current |
| Banumathi Srinivasan | Director | 19 Mar 2025 | 1 Years 7 Months | Current |
Auditor
Inex Medicaments Private Limited is audited by R C KRISHNEN & CO for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| R C KRISHNEN & CO | FY 2023 | 008985S |
Shareholding
The shareholding of Inex Medicaments Private Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Inex Medicaments Private Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 13 May 2016 | 100038012 | Others | ₹2.25 Cr | Open |
To see the full charge records of Inex Medicaments Private Limited, buy the company report.
Total charge records: 1 View all charges
Legal cases
No court or tribunal cases involving Inex Medicaments Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Inex Medicaments Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Inex Medicaments has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 33AACCI1653E1Z2 | Tamil Nadu | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Inex Medicaments Private Limited, buy the company report.
Recent activity
Inex Medicaments Private Limited has 13 board changes on record since 2009: 3 appointments and 10 cessations. The latest: Ajithkumar ceased to be Director on 19 Mar 2025.
6 earlier events are in the company report.
Frequently asked questions
Inex Medicaments is an active private limited company based in Chennai, Tamil Nadu, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 06 November 2009 (17+ years old) and is registered under CIN U51909TN2009PTC073452.
Inex Medicaments has 2 current directors:
- Gopalakrishnan Srinivasan - Managing Director
- Banumathi Srinivasan - Director
The latest financial statements of Inex Medicaments on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Inex Medicaments is 33AACCI1653E1Z2, registered in Tamil Nadu.
The CIN (Corporate Identification Number) of Inex Medicaments is U51909TN2009PTC073452. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Inex Medicaments was incorporated on 06 November 2009, making it 17+ years old. It is registered with the Registrar of Companies, Chennai.
Ajithkumar ceased to be Director on 19 Mar 2025. Banumathi Srinivasan was appointed as Director on 19 Mar 2025. Damodaran Sampath Kumar ceased to be Director on 27 Aug 2013. Inex Medicaments has 13 board changes on record in total.
Inex Medicaments can be reached through the website inexmedicaments.com. Its registered office is in Chennai, Tamil Nadu, India.
The registered office of Inex Medicaments is at No.22 Villa A&B Second Floor Rajiv Street Kamaraj Nagar Keelkatta, Chennai, Tamil Nadu, India – 600117.
Inex Medicaments operates in the pharma industry, in the drug formulation and development segment.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
